Clinical Trials

372 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

174 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

GastrointestinalGenitourinaryGynecologic

89 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06161532 2026-04-14

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03047213 2026-04-13

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

17 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

46 enrolled

Carcinoma, Transitional Cell

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

15 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07506057 2026-04-01

SHIELD

GastrointestinalGenitourinary

20 enrolled

Biliary Tract Neoplasms, Carcinoma, Transitional Cell

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

44 enrolled

Carcinoma, Transitional Cell

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

60 enrolled

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

10 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

12 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

24 enrolled

Carcinoma, Transitional Cell

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

520 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

256 enrolled